Form 4: CG Oncology Director's Firm Buys $50M in Shares

A firm managed by CG Oncology Director Brian Guan-Chyun Liu acquired 1,515,151 shares of common stock for approximately $50 million.

Summary

• Brian Guan-Chyun Liu, a Director of CG Oncology, Inc. (CGON), reported an indirect acquisition of common stock.
• The transaction involved the purchase of 1,515,151 shares of CGON Common Stock.
• The shares were acquired at a price of $33.00 per share.
• The total value of the acquisition was approximately $49,999,983.
• The transaction occurred on September 11, 2025.
• The shares are beneficially owned indirectly by Seven Fleet Partners LP.
• Mr. Liu is the managing member of Seven Fleet Advisors, LLC, the investment manager of Seven Fleet Partners, LP.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 8

Explanation: The substantial indirect acquisition of common stock by a firm associated with a director, totaling nearly $50 million, indicates strong insider confidence in CG Oncology's future prospects and valuation.

Positives

• Significant insider buying by a firm associated with a director, totaling approximately $50 million, often signals confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned acquisition strategy.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

Insider purchases, especially of this magnitude, can be interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or has significant growth potential. This is particularly relevant in the biotechnology sector where future success often hinges on clinical trial outcomes and regulatory approvals.

Comparison to Industry Standards

• This filing reports a specific insider transaction and does not provide data for direct comparison to industry-wide financial benchmarks or competitor performance. The significance lies in the insider's conviction rather than comparative financial metrics.

Related Party Transactions

• The acquisition of shares by Seven Fleet Partners LP, an entity for which Brian Guan-Chyun Liu (a Director) serves as the managing member of its investment manager, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this significant insider purchase as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.

Key Dates

Recommendation

The substantial indirect purchase of CG Oncology shares by a firm managed by a company director, totaling nearly $50 million, signals strong insider confidence. Such a significant investment, especially when executed under a Rule 10b5-1 plan, suggests that those closest to the company believe its stock is currently undervalued or poised for significant future growth. This insider conviction provides a compelling reason for investors to consider a "buy" recommendation.

Keywords

CG Oncology, CGON, Insider Trading, Form 4, Stock Acquisition, Director, Beneficial Ownership, Rule 10b5-1, Equity Purchase, Biotechnology